annual CFF:
-$5.24B+$825.72M(+13.61%)Summary
- As of today (August 20, 2025), GSK annual cash flow from financing activities is -$5.24 billion, with the most recent change of +$825.72 million (+13.61%) on December 31, 2024.
- During the last 3 years, GSK annual CFF has risen by +$4.14 billion (+44.14%).
- GSK annual CFF is now -206.96% below its all-time high of $4.90 billion, reached on December 31, 2018.
Performance
GSK Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$2.78B-$4.02B(-323.90%)Summary
- As of today (August 20, 2025), GSK quarterly cash flow from financing activities is -$2.78 billion, with the most recent change of -$4.02 billion (-323.90%) on June 30, 2025.
- Over the past year, GSK quarterly CFF has dropped by -$1.12 billion (-67.66%).
- GSK quarterly CFF is now -123.89% below its all-time high of $11.63 billion, reached on June 30, 2018.
Performance
GSK quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$3.92B-$1.12B(-40.03%)Summary
- As of today (August 20, 2025), GSK TTM cash flow from financing activities is -$3.92 billion, with the most recent change of -$1.12 billion (-40.03%) on June 30, 2025.
- Over the past year, GSK TTM CFF has increased by +$5.22 billion (+57.11%).
- GSK TTM CFF is now -138.76% below its all-time high of $10.11 billion, reached on March 31, 2019.
Performance
GSK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
GSK Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.6% | -67.7% | +57.1% |
| 3 y3 years | +44.1% | +51.3% | -3476.1% |
| 5 y5 years | -338.1% | +1.2% | +58.4% |
GSK Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -355.9% | +44.1% | -323.9% | +51.3% | -292.9% | +57.1% |
| 5 y | 5-year | -355.9% | +55.9% | -125.7% | +51.3% | -222.7% | +68.5% |
| alltime | all time | -207.0% | +55.9% | -123.9% | +51.3% | -138.8% | +68.5% |
GSK Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$2.78B(-323.9%) | -$3.92B(+40.0%) |
| Mar 2025 | - | $1.24B(-246.8%) | -$2.80B(-47.1%) |
| Dec 2024 | -$5.24B(-13.6%) | -$845.20M(-45.1%) | -$5.29B(-37.8%) |
| Sep 2024 | - | -$1.54B(-7.1%) | -$8.51B(-6.9%) |
| Jun 2024 | - | -$1.66B(+32.1%) | -$9.14B(+29.8%) |
| Mar 2024 | - | -$1.25B(-69.1%) | -$7.04B(+16.6%) |
| Dec 2023 | -$6.07B(-396.3%) | -$4.06B(+87.5%) | -$6.04B(+83.7%) |
| Sep 2023 | - | -$2.17B(-592.9%) | -$3.29B(+14.7%) |
| Jun 2023 | - | $439.58M(-276.5%) | -$2.87B(-68.2%) |
| Mar 2023 | - | -$249.08M(-81.0%) | -$9.01B(-543.3%) |
| Dec 2022 | $2.05B(-121.8%) | -$1.31B(-24.9%) | $2.03B(>+9900.0%) |
| Sep 2022 | - | -$1.75B(-69.4%) | $14.09M(-112.8%) |
| Jun 2022 | - | -$5.70B(-152.8%) | -$109.63M(-103.4%) |
| Mar 2022 | - | $10.79B(-424.2%) | $3.19B(-134.1%) |
| Dec 2021 | -$9.39B(-21.1%) | -$3.33B(+78.0%) | -$9.37B(+9.4%) |
| Sep 2021 | - | -$1.87B(-22.0%) | -$8.57B(-28.7%) |
| Jun 2021 | - | -$2.40B(+35.0%) | -$12.02B(-3.3%) |
| Mar 2021 | - | -$1.78B(-29.7%) | -$12.43B(+4.6%) |
| Dec 2020 | -$11.89B(+893.5%) | -$2.53B(-52.5%) | -$11.88B(-4.3%) |
| Sep 2020 | - | -$5.32B(+89.1%) | -$12.42B(+31.8%) |
| Jun 2020 | - | -$2.81B(+129.5%) | -$9.42B(+28.5%) |
| Mar 2020 | - | -$1.23B(-60.0%) | -$7.33B(+518.4%) |
| Dec 2019 | -$1.20B(-124.4%) | -$3.06B(+32.1%) | -$1.19B(-43.6%) |
| Sep 2019 | - | -$2.32B(+220.3%) | -$2.10B(-5.9%) |
| Jun 2019 | - | -$724.11M(-114.7%) | -$2.23B(-122.1%) |
| Mar 2019 | - | $4.92B(-223.6%) | $10.11B(+105.0%) |
| Dec 2018 | $4.90B(-168.1%) | -$3.98B(+62.3%) | $4.93B(-5.4%) |
| Sep 2018 | - | -$2.45B(-121.1%) | $5.22B(-23.5%) |
| Jun 2018 | - | $11.63B(-4567.5%) | $6.82B(-219.9%) |
| Mar 2018 | - | -$260.23M(-93.0%) | -$5.69B(-20.8%) |
| Dec 2017 | -$7.20B(-6.3%) | -$3.70B(+334.8%) | -$7.18B(+55.3%) |
| Sep 2017 | - | -$850.57M(-2.9%) | -$4.62B(-36.7%) |
| Jun 2017 | - | -$876.28M(-50.1%) | -$7.30B(-5.2%) |
| Mar 2017 | - | -$1.75B(+53.8%) | -$7.70B(+0.2%) |
| Dec 2016 | -$7.69B(-20.2%) | -$1.14B(-67.7%) | -$7.69B(-6.5%) |
| Sep 2016 | - | -$3.53B(+176.4%) | -$8.22B(+18.8%) |
| Jun 2016 | - | -$1.28B(-26.5%) | -$6.92B(-21.7%) |
| Mar 2016 | - | -$1.74B(+3.9%) | -$8.84B(-8.7%) |
| Dec 2015 | -$9.64B(+25.1%) | -$1.67B(-25.0%) | -$9.68B(-4.6%) |
| Sep 2015 | - | -$2.23B(-30.2%) | -$10.14B(+24.8%) |
| Jun 2015 | - | -$3.20B(+24.1%) | -$8.13B(+32.3%) |
| Mar 2015 | - | -$2.58B(+20.5%) | -$6.14B(-7.2%) |
| Dec 2014 | -$7.70B(-0.4%) | -$2.14B(+894.5%) | -$6.62B(-0.8%) |
| Sep 2014 | - | -$214.98M(-82.3%) | -$6.67B(-16.4%) |
| Jun 2014 | - | -$1.21B(-60.3%) | -$7.98B(-16.2%) |
| Mar 2014 | - | -$3.05B(+39.3%) | -$9.52B(+23.2%) |
| Dec 2013 | -$7.73B(+90.7%) | -$2.19B(+43.4%) | -$7.73B(+17.1%) |
| Sep 2013 | - | -$1.53B(-44.5%) | -$6.60B(-4.3%) |
| Jun 2013 | - | -$2.75B(+118.2%) | -$6.90B(+97.9%) |
| Mar 2013 | - | -$1.26B(+18.8%) | -$3.49B(-14.0%) |
| Dec 2012 | -$4.05B(-53.7%) | -$1.06B(-41.9%) | -$4.06B(-8.6%) |
| Sep 2012 | - | -$1.83B(-375.9%) | -$4.44B(-19.8%) |
| Jun 2012 | - | $662.37M(-136.2%) | -$5.53B(-34.6%) |
| Mar 2012 | - | -$1.83B(+26.7%) | -$8.46B(-3.8%) |
| Dec 2011 | -$8.76B | -$1.45B(-50.5%) | -$8.80B(+1.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2011 | - | -$2.92B(+28.9%) | -$8.64B(+25.0%) |
| Jun 2011 | - | -$2.27B(+4.9%) | -$6.91B(-2.3%) |
| Mar 2011 | - | -$2.16B(+67.7%) | -$7.07B(-4.4%) |
| Dec 2010 | -$7.40B(+136.6%) | -$1.29B(+8.0%) | -$7.40B(-5.7%) |
| Sep 2010 | - | -$1.19B(-50.9%) | -$7.85B(+68.4%) |
| Jun 2010 | - | -$2.43B(-2.4%) | -$4.66B(-7.5%) |
| Mar 2010 | - | -$2.49B(+43.1%) | -$5.04B(+61.0%) |
| Dec 2009 | -$3.13B(-48.1%) | -$1.74B(-187.1%) | -$3.13B(-3.0%) |
| Sep 2009 | - | $2.00B(-171.2%) | -$3.23B(-62.8%) |
| Jun 2009 | - | -$2.81B(+383.2%) | -$8.67B(+662.6%) |
| Mar 2009 | - | -$580.56M(-68.4%) | -$1.14B(-81.1%) |
| Dec 2008 | -$6.02B(+107.9%) | -$1.84B(-46.8%) | -$6.02B(+303.6%) |
| Sep 2008 | - | -$3.45B(-172.9%) | -$1.49B(+172.3%) |
| Jun 2008 | - | $4.73B(-186.5%) | -$548.18M(-92.4%) |
| Mar 2008 | - | -$5.47B(-302.9%) | -$7.26B(+149.6%) |
| Dec 2007 | -$2.90B(-64.0%) | $2.70B(-207.6%) | -$2.91B(-60.3%) |
| Sep 2007 | - | -$2.50B(+26.3%) | -$7.32B(+12.6%) |
| Jun 2007 | - | -$1.98B(+77.7%) | -$6.50B(-11.9%) |
| Mar 2007 | - | -$1.12B(-35.0%) | -$7.37B(-7.7%) |
| Dec 2006 | -$8.05B(+83.9%) | -$1.72B(+2.0%) | -$7.99B(-15.8%) |
| Sep 2006 | - | -$1.68B(-41.1%) | -$9.49B(+3.3%) |
| Jun 2006 | - | -$2.86B(+64.7%) | -$9.18B(+128.7%) |
| Mar 2006 | - | -$1.73B(-46.0%) | -$4.02B(-8.5%) |
| Dec 2005 | -$4.38B(-22.9%) | -$3.21B(+133.0%) | -$4.39B(+142.4%) |
| Sep 2005 | - | -$1.38B(-159.7%) | -$1.81B(-33.4%) |
| Jun 2005 | - | $2.31B(-209.6%) | -$2.72B(-49.9%) |
| Mar 2005 | - | -$2.11B(+232.8%) | -$5.42B(-3.5%) |
| Dec 2004 | -$5.68B(+27.1%) | -$633.91M(-72.3%) | -$5.62B(+5.3%) |
| Sep 2004 | - | -$2.29B(+482.3%) | -$5.34B(+19.3%) |
| Jun 2004 | - | -$392.51M(-83.0%) | -$4.47B(-20.3%) |
| Mar 2004 | - | -$2.31B(+552.5%) | -$5.61B(+26.9%) |
| Dec 2003 | -$4.47B(-26.0%) | -$353.53M(-75.1%) | -$4.42B(-7.9%) |
| Sep 2003 | - | -$1.42B(-7.2%) | -$4.80B(+1.1%) |
| Jun 2003 | - | -$1.53B(+36.8%) | -$4.75B(-15.7%) |
| Mar 2003 | - | -$1.12B(+52.3%) | -$5.64B(-6.8%) |
| Dec 2002 | -$6.04B(+8.7%) | -$734.38M(-46.4%) | -$6.06B(-24.7%) |
| Sep 2002 | - | -$1.37B(-43.4%) | -$8.04B(+10.2%) |
| Jun 2002 | - | -$2.42B(+58.0%) | -$7.29B(+16.1%) |
| Mar 2002 | - | -$1.53B(-43.6%) | -$6.28B(+13.3%) |
| Dec 2001 | -$5.56B(+29.3%) | -$2.72B(+335.8%) | -$5.54B(+51.7%) |
| Sep 2001 | - | -$623.42M(-55.8%) | -$3.65B(+19.9%) |
| Jun 2001 | - | -$1.41B(+77.8%) | -$3.05B(+81.7%) |
| Mar 2001 | - | -$793.36M(-4.1%) | -$1.68B(+102.7%) |
| Dec 2000 | -$4.30B(+22.4%) | -$827.58M(+4812.2%) | -$827.58M(<-9900.0%) |
| Sep 2000 | - | -$16.85M(-57.2%) | $100.00(-100.0%) |
| Jun 2000 | - | -$39.35M(-170.0%) | $16.85M(-70.0%) |
| Mar 2000 | - | $56.19M | $56.19M |
| Dec 1999 | -$3.51B(+146.4%) | - | - |
| Dec 1998 | -$1.43B(-28.0%) | - | - |
| Dec 1997 | -$1.98B(-25.5%) | - | - |
| Dec 1996 | -$2.66B(-179.0%) | - | - |
| Dec 1995 | $3.36B(+5659.7%) | - | - |
| Jun 1994 | $58.39M(-108.1%) | - | - |
| Jun 1993 | -$718.86M(-56.2%) | - | - |
| Jun 1992 | -$1.64B(+265.1%) | - | - |
| Jun 1991 | -$449.64M | - | - |
FAQ
- What is GSK plc annual cash flow from financing activities?
- What is the all time high annual CFF for GSK plc?
- What is GSK plc annual CFF year-on-year change?
- What is GSK plc quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for GSK plc?
- What is GSK plc quarterly CFF year-on-year change?
- What is GSK plc TTM cash flow from financing activities?
- What is the all time high TTM CFF for GSK plc?
- What is GSK plc TTM CFF year-on-year change?
What is GSK plc annual cash flow from financing activities?
The current annual CFF of GSK is -$5.24B
What is the all time high annual CFF for GSK plc?
GSK plc all-time high annual cash flow from financing activities is $4.90B
What is GSK plc annual CFF year-on-year change?
Over the past year, GSK annual cash flow from financing activities has changed by +$825.72M (+13.61%)
What is GSK plc quarterly cash flow from financing activities?
The current quarterly CFF of GSK is -$2.78B
What is the all time high quarterly CFF for GSK plc?
GSK plc all-time high quarterly cash flow from financing activities is $11.63B
What is GSK plc quarterly CFF year-on-year change?
Over the past year, GSK quarterly cash flow from financing activities has changed by -$1.12B (-67.66%)
What is GSK plc TTM cash flow from financing activities?
The current TTM CFF of GSK is -$3.92B
What is the all time high TTM CFF for GSK plc?
GSK plc all-time high TTM cash flow from financing activities is $10.11B
What is GSK plc TTM CFF year-on-year change?
Over the past year, GSK TTM cash flow from financing activities has changed by +$5.22B (+57.11%)